Peptide News Digest

#Axios

2 stories

Industry · View digest

General Bio Raises $7.4 Million Seed Round to Advance an Oral Peptide Delivery Platform for GLP-1 Weight-Loss Drugs and Other Peptide Therapeutics According to Monday July 20 Axios Pro Biotech Deals Exclusive Reporting; CEO David Kim Confirmed the Company Is Pursuing a Larger Follow-On Round to Scale Preclinical and Early Clinical Development Against Established Oral-Peptide Competitors Including Novo Nordisk's Wegovy Pill (Oral Semaglutide 25 mg), Merck's LIPFENDRA (Enlicitide) Oral PCSK9 Inhibitor, and MindRank AI's MDR-001 Phase 3 Chinese Oral GLP-1

General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger follow-on funding round, CEO David Kim told Axios Pro Biotech Deals in an exclusive report published Monday July 20, 2026. The company is one of several new-generation oral peptide startups seeking to compete against the established oral-peptide market, which now spans Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, launched January 2026, over 3 million US prescriptions by June), Merck's LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor FDA-approved July 16, 2026), and MindRank AI's MDR-001 (AI-designed oral small-molecule GLP-1RA in Phase 3 MOBILE trial in China, $52M Series B closed July 9). The oral peptide category economics are shaped by macrocyclic peptide chemistry (Merck's LIPFENDRA approach) that allows survival through the gastrointestinal tract, permeation-enhancer formulations (Novo's SNAC technology for oral semaglutide), and next-generation delivery platforms including Rani Therapeutics' RaniPill capsule (July 9 collaboration announced with China's PegBio). Seed-stage entrants like General Bio typically position on proprietary chemistry or delivery mechanisms that could enable next-generation peptides beyond the current oral GLP-1 wave.

Industry · View digest

Axios (July 7): Chinese Fentanyl Precursor Manufacturers Pivot to Gray-Market Peptide Sales, Per Chainalysis Blockchain Analysis: Q1 2026 Crypto Payments to Gray-Market Peptide Vendors Reached $27 Million, Up Nearly 150% From Q4 2025

Axios reported Tuesday July 7, 2026 that blockchain analysis firm Chainalysis has identified a supply-chain shift in which Chinese manufacturers of fentanyl chemical precursors are pivoting into the US gray-market peptide trade. Q1 2026 crypto payments to gray-market peptide vendors reached $27 million, up nearly 150% from Q4 2025. One China-based company previously identified through its digital cryptocurrency wallet as a seller of fentanyl precursors reappeared on message boards selling cosmetic and weight-loss peptides. Chainalysis senior intelligence analyst Sara Graham characterized the shift bluntly: 'For these manufacturers that decided to pivot, it was really a business decision. They departed from a trade in which they could be sanctioned or indicted by the US and reappeared in a very lucrative scene that has widespread buy-in.' The pivot happens against a regulatory backdrop where compounded GLP-1 supply through 503B outsourcing facilities is closing (FDA proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list on April 30, 2026), pushing gray-market demand toward alternative channels. Traditional US banks and credit-card processors decline the peptide-vendor transactions, so crypto has become the dominant payment rail. The Chainalysis findings extend the earlier Fortune June 4 piece on the $100 million gray-market looksmaxxing peptide economy.